All
Extended Adjuvant Treatment With Neratinib Improves DFS in Breast Cancer
July 24th 2014Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab.
Vemurafenib- Cobimetinib Combo Improves PFS in Phase III Melanoma Trial
July 14th 2014The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.
First FDA Breakthrough Designation Granted to CAR Therapy
July 11th 2014The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Aprepitant and Metoclopramide Similarly Effective for Prevention of Delayed Cisplatin-Induced Emesis
July 2nd 2014For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.
Companion Website for “The Story of Cancer†Documentary Launches as Part of a National Outreach
May 27th 2014WETA, the Washington, DC, public television station, has launched a new website as part of a national outreach for the documentary The Story of Cancer: The Emperor of All Maladies, which will be produced by Ken Burns.
Panitumumab Gains FDA Approval for KRAS Wild-Type mCRC
May 24th 2014The FDA has approved panitumumab (Vectibix) in combination with chemotherapy as a frontline treatment for patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC), based on findings from two phase III clinical trials.